Drug Profile
DB 105
Alternative Names: ORM-12741Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Orion
- Developer Johnson & Johnson Innovative Medicine; Orion; University of Cape Town; University of Oxford
- Class Antidementias; Antipsychotics
- Mechanism of Action Alpha 2c adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Raynaud's disease; Schizophrenia
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 18 Jun 2019 Orion Corporation has licensed DB105 to Denovo Biopharma, worldwide for the treatment of Alzheimer's disease
- 03 May 2018 Discontinued - Phase-I for Alzheimer's disease (In volunteers) in South Africa (PO)